Amarin Corporation PLC (AMRN) insider have most recently took part in a trading activity. On Nov 30, 2017 Thero John F, President and CEO bought 10,000 shares having total worth of $32,400 at the price of $3.24 per share, following the transaction a total of 1,135,003 shares owned by Thero John F.
Furthermore, over the past 12 months , the stock was traded 1 times by insiders. In 1 of these trades, the insider was a seller .
Shares of Amarin Corporation PLC (AMRN) traded down 2.14% on Dec 1, 2017, hitting $3.2. 950,455 shares of the company’s stock traded hands. Amarin Corporation PLC has a 52 week low of $1.97 and a 52 week high of $4.29. The company’s market cap is $602 million.
Amarin Corporation PLC (AMRN) last announced its earnings results on Nov 1, 2017. The company reported -0.04 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.05 by $0.01. The company had revenue of $47 million for the quarter, compared to the consensus estimate of $46 million. During the same quarter in the previous year, the company posted -0.08 earnings per share. The company’s revenue for the quarter was up 45% on a year-over-year basis.
|earnings per share||-0.04||-0.05||-0.08||-0.04||-0.08||-0.09||-0.14||-0.10||-0.14||-0.15|
Amarin Corporation PLC formerly Ethical Holdings plc is a public limited company incorporated under the laws of England and Wales. It was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993. The Company is a biopharmaceutical company that commercializes and develops therapeutics to improve cardiovascular health. On July 26, 2012, it received approval from the U.S. Food and Drug Administration, or FDA, to market and sell its product Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe (TGï‚³500mg/dL) hypertriglyceridemia, which it sometimes refers to as the MARINE indication. Vascepa became commercially available in the United States by prescription in January 2013, when it commenced sales and shipments to their network of U.S.-based wholesalers. On January 28, 2013, it commenced full commercial launch of Vascepa in the United States for the MARINE indication. The Company is also developing Vascepa for the treatment of patients with high (TG ï‚³ 200 mg/dL and <500 mg/dL) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C, levels which it refers to as mixed dyslipidemia. The biotechnology and pharmaceutical industries are highly competitive. There are many pharmaceutical companies, biotechnology companies, public and private universities and research organizations actively engaged in the research and development of products that may be similar to its products. The Company 's potential competitors both in the United States and Europe include large, well-established pharmaceutical companies, specialty pharmaceutical sales and marketing companies and specialized cardiovascular treatment companies. Any product development activities related to Vascepa or products that it may develop or acquire in the future will be subject to extensive regulation by various government authorities, including the FDA and comparable regulatory authorities in other countries, which regulate the design, research, clinical and non-clinical development, testing, manufacturing, storage, distribution, import, export, labeling, advertising and marketing of pharmaceutical products and devices.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018